Cargando…

Targeting DNA Repair Pathways in Hematological Malignancies

DNA repair plays an essential role in protecting cells that are repeatedly exposed to endogenous or exogenous insults that can induce varying degrees of DNA damage. Any defect in DNA repair mechanisms results in multiple genomic changes that ultimately may result in mutation, tumor growth, and/or ce...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alhmoud, Jehad F., Mustafa, Ayman G., Malki, Mohammed Imad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7582413/ https://www.ncbi.nlm.nih.gov/pubmed/33036137 http://dx.doi.org/10.3390/ijms21197365

Ejemplares similares

DNA Damage/Repair Management in Cancers
por: Alhmoud, Jehad F., et al.
Publicado: (2020)

Investigation of the Effect of Imatinib and Hydroxyurea Combination Therapy on Hematological Parameters and Gene Expression in Chronic Myeloid Leukemia (CML) Patients
por: Al-Amleh, Esraa K., et al.
Publicado: (2022)

Therapeutic Targeting of Notch Signaling Pathway in Hematological Malignancies
por: Sorrentino, Claudia, et al.
Publicado: (2019)

Targeting the canonical Wnt/β-catenin pathway in hematological malignancies
por: Ashihara, Eishi, et al.
Publicado: (2015)

Targeting the mitochondrial apoptotic pathway: a preferred approach in hematologic malignancies?
por: Brinkmann, K, et al.
Publicado: (2014)

Targeting Protein Degradation Pathways in Tumors: Focusing on their Role in Hematological Malignancies
por: Wolska-Washer, Anna, et al.
Publicado: (2022)

Targeting immune checkpoints in hematological malignancies
por: Salik, Basit, et al.
Publicado: (2020)

The DNA methylation landscape of hematological malignancies: an update
por: Blecua, Pedro, et al.
Publicado: (2020)

Role of Circulating Tumor DNA in Hematological Malignancy
por: Ogawa, Miho, et al.
Publicado: (2021)

Role of Wnt canonical pathway in hematological malignancies
por: GE, Xueling, et al.
Publicado: (2010)

Invasive Fungal Infections and Targeted Therapies in Hematological Malignancies
por: Little, Jessica S., et al.
Publicado: (2021)

BCL-2 as therapeutic target for hematological malignancies
por: Perini, Guilherme Fleury, et al.
Publicado: (2018)

Targeting the integrated stress response in hematologic malignancies
por: Nwosu, Gus O., et al.
Publicado: (2022)

Targeting nuclear import and export in hematological malignancies
por: Nachmias, Boaz, et al.
Publicado: (2020)

Emerging Metabolic Targets in the Therapy of Hematological Malignancies
por: Leni, Zaira, et al.
Publicado: (2013)

Targeting p53 by small molecules in hematological malignancies
por: Saha, Manujendra N, et al.
Publicado: (2013)

Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies
por: Tibes, Raoul, et al.
Publicado: (2014)

Impact of Histone Modifications and Their Therapeutic Targeting in Hematological Malignancies
por: Markouli, Mariam, et al.
Publicado: (2022)

Protein Arginine Methyltransferases as Therapeutic Targets in Hematological Malignancies
por: Sauter, Camille, et al.
Publicado: (2022)

Targeting CD22 for B-cell hematologic malignancies
por: Xu, Jia, et al.
Publicado: (2023)

The French Cohort of DNA Repair-Deficient Xeroderma Pigmentosum Patients: Risk of Hematological Malignancies
por: Sarasin, Alain
Publicado: (2023)

Theranostic Potentials of Gold Nanomaterials in Hematological Malignancies
por: Shakil, Md Salman, et al.
Publicado: (2022)

The treatment of hematologic malignancies in pregnancy
por: Vandenbriele, C., et al.
Publicado: (2010)

Deubiquitinases in hematological malignancies
por: Lei, Hu, et al.
Publicado: (2021)

Autophagy in Hematological Malignancies
por: García Ruiz, Olga, et al.
Publicado: (2022)

Target Therapy in Hematological Malignances: New Monoclonal Antibodies
por: Podhorecka, Monika, et al.
Publicado: (2014)

Involvement of classic and alternative non-homologous end joining pathways in hematologic malignancies: targeting strategies for treatment
por: Valikhani, Mohsen, et al.
Publicado: (2021)

Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
por: He, Yonghan, et al.
Publicado: (2020)

Super-enhancers: critical roles and therapeutic targets in hematologic malignancies
por: Jia, Yunlu, et al.
Publicado: (2019)

CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies
por: Testa, Ugo, et al.
Publicado: (2019)

Nanomedicine for Immunotherapy Targeting Hematological Malignancies: Current Approaches and Perspective
por: Allegra, Alessandro, et al.
Publicado: (2021)

Targeting macrophages in hematological malignancies: recent advances and future directions
por: Li, Wei, et al.
Publicado: (2022)

Risk of Infections Secondary to the Use of Targeted Therapies in Hematological Malignancies
por: Andreescu, Mihaela
Publicado: (2023)

The hedgehog pathway in hematopoiesis and hematological malignancy
por: Lemos, Tucker, et al.
Publicado: (2022)

Isotype-specific inhibition of the phosphatidylinositol-3-kinase pathway in hematologic malignancies
por: Castillo, Jorge J, et al.
Publicado: (2014)

Molecular-Targeted Therapies for Hematologic Malignancies
por: Bunting, Kevin D., et al.
Publicado: (2012)

The Challenge of Targeting Notch in Hematologic Malignancies
por: Hernandez Tejada, Fiorela N., et al.
Publicado: (2014)

CircRNAs in hematopoiesis and hematological malignancies
por: Bonizzato, A, et al.
Publicado: (2016)

HMGA Proteins in Hematological Malignancies
por: Minervini, Angela, et al.
Publicado: (2020)

Vorinostat in solid and hematologic malignancies
por: Siegel, David, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_qc7nerup6splogdblmts4bbmue